Clinical trial · no report yet · Phase 2/Phase 3

COSI trial (CPX-351): what clinicians have said so far

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

NCT04217278 ↗
Active, not recruiting
University of Birmingham
Focused size, estimated: 1–150 verified statements once built

We haven't built an HCP commentary report on COSI (CPX-351; TBF; Mini-TBF in AML or high-risk MDS undergoing allogeneic SCT) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on COSI so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
2 YouTube videos, typically up to 9 once built
2 posts on X, typically up to 9 once built

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: An International Randomised Clinical Trial of Therapeutic Interventions to Assess the Effects on Outcome in Adults With Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation.
Phase: Phase 2/Phase 3
Status: Active, not recruiting
Conditions: Acute Myeloid Leukaemia; High-risk Myelodysplastic Syndrome
Interventions: Vyxeos; Fludarabine; Busulphan; Thiotepa; Cytarabine
Arms: R1: Intermediate dose Cytarabine · Active comparator
R1: Vyxeos · Experimental
R2: FB4 · Active comparator
R2: TBF · Experimental
R3: FB2 · Active comparator
Mini-TBF · Experimental
Enrollment: 333
Primary outcomes: Overall survival (all randomisations)
Sponsor: University of Birmingham with Jazz Pharmaceuticals, Adienne SA
Start: Jan 27, 2020
Primary completion: May 2026 (estimated)
Results posted: No
Registry record: NCT04217278 · updated May 5, 2026